Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.

Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P.

Am J Kidney Dis. 2013 Feb;61(2):289-99. doi: 10.1053/j.ajkd.2012.07.028. Epub 2012 Nov 7. Review.

PMID:
23141475
2.

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S.

Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Review.

PMID:
27346521
3.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

4.
5.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

6.

The alternative pathway of complement and the thrombotic microangiopathies.

Teoh CW, Riedl M, Licht C.

Transfus Apher Sci. 2016 Apr;54(2):220-31. doi: 10.1016/j.transci.2016.04.012. Epub 2016 Apr 26. Review.

PMID:
27160864
7.

Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.

Fakhouri F, Frémeaux-Bacchi V, Loirat C.

Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Review.

PMID:
23756030
8.

Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C.

Semin Thromb Hemost. 2014 Jun;40(4):444-64. doi: 10.1055/s-0034-1376153. Epub 2014 Jun 9. Review.

PMID:
24911558
9.

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.

Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.

Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594.

10.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
11.

An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.

Sengul Samanci N, Ayer M, Ergen A, Ozturk S.

Transfus Apher Sci. 2015 Jun;52(3):314-6. doi: 10.1016/j.transci.2015.01.006. Epub 2015 Jan 12.

PMID:
25634788
12.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

13.

Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.

Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.

Pediatrics. 2014 Jun;133(6):e1759-63. doi: 10.1542/peds.2013-1787.

14.

Clinical grand rounds: atypical hemolytic uremic syndrome.

Hodgkins KS, Bobrowski AE, Lane JC, Langman CB.

Am J Nephrol. 2012;35(5):394-400. doi: 10.1159/000337954. Epub 2012 Apr 18.

15.

[Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].

Kistler AD.

Praxis (Bern 1994). 2016 Mar 30;105(7):389-96. doi: 10.1024/1661-8157/a002308. Review. German.

PMID:
27005733
16.

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.

Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1312-6. doi: 10.2215/CJN.01090209. Epub 2009 Jun 25.

17.

Eculizumab in atypical hemolytic-uremic syndrome.

Tanimoto T, Oshima Y, Kami M.

N Engl J Med. 2013 Oct 3;369(14):1378-9. doi: 10.1056/NEJMc1308826#SA4. No abstract available.

PMID:
24088109
18.

Eculizumab in atypical hemolytic-uremic syndrome.

Kistler AD.

N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826#SA3. No abstract available.

19.

Eculizumab in atypical hemolytic-uremic syndrome.

Amadio A, Tejani AM.

N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826#SA2. No abstract available.

PMID:
24088107
20.

Eculizumab in atypical hemolytic-uremic syndrome.

Ring T.

N Engl J Med. 2013 Oct 3;369(14):1377-8. doi: 10.1056/NEJMc1308826#SA1. No abstract available.

PMID:
24088106

Supplemental Content

Support Center